"Every effort should be made to reduce the cost of molecular testing and expand their access," writes Ashley Ross, MD, PhD.
A new study examining gene expression assays for stratifying prostate cancer risk is suggesting that it may be possible to develop lower-cost alternatives and expand access.
This article discusses the risk of depression and suicide in men, focusing on increased risk in men with genitourinary cancer and other urologic conditions.
The urologist argued that he did obtain informed consent to the injection treatment, noting that the patient had signed a document that explained that scars were a possible outcome.
“If the PRECISION study results hold up in future research, any time you can avoid an invasive procedure with risks, obviously that’s good for patients,” says one urologist.
While a recent study of salvage radical prostatectomy after focal therapy demonstrates satisfactory functional outcomes, oncologic outcomes were not as good as after primary RP, said researcher Jaime O. Herrera-Caceres, MD.
Recent data support the product’s use in protecting organs at risk for radiation exposure.
"This important study provides strong validation of the utility of multiparametric MRI of the prostate prior to initial biopsy," writes Badar M. Mian, MD.
The benefits of bilateral nerve-sparing procedures in men undergoing radical prostatectomy may be concentrated in those patients who have high sexual function at baseline.
Abiraterone acetate (ZYTIGA) should be considered a standard of care for newly diagnosed, metastatic, non-castrate prostate cancer, as should docetaxel (Taxotere), according to a new clinical practice guideline from ASCO.